Genomic Testing Cooperative Unveils “GTC Interpret,” a Groundbreaking Web-Based Platform for Partner Labs to Access Analyzed Sequencing Data and Finalize Reports

LAKE FOREST, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a new web-based platform designed to provide Co-Op member laboratories and partner labs seamless online access to fully analyze genomic data with sophisticated reporting tools. With GTC Interpret, users can now access a wealth of detailed genomic information, all generated through GTC’s cutting-edge, AI-driven Interprestation software suite.

The platform enables access to a comprehensive range of next generation sequencing (NGS) DNA and RNA data, including sequencing quality control, detected DNA and RNA variants, tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), Epstein-Barr virus (EBV), human papillomavirus (HPV), and Torque Teno Virus (TTV). Additionally, users can access details on MET14, EGFRviii, and other genes' alternative splicing data, RNA fusions, chromosomal changes, gene copy numbers, HLA genotyping, RNA expression levels, B-cell (heavy and light chains) and T-cell clonality (T-cell receptors of alpha, beta, gamma, and delta genes) with their specific clonotype. The platform also gives access to BAM file images highlighting and comparing detected DNA and RNA variants allowing for a clear, visual confirmation of results.

To ensure all findings are clinically relevant, GTC Interpret shows complete curation of every detected variant. Clients with adequate training can perform AI-assisted cancer diagnosis and classification directly on the platform using a variety of powerful algorithms, including deep learning, random forest, extreme gradient boost, support vector machines, and Bayesian-based modeling.

“GTC was established to advance the science and clinical utilization of genomics and to democratize these advances. The aim of launching this web-based access to detailed genomic data is to make it easy for pathologists and clinicians to see and evaluate the cancer they are dealing with,” stated Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC. “Each cancer and each patient are different and genomics, especially with RNA data, provide tremendous insight to the disease and the host. We are making this comprehensive information available to pathologists and treating physicians,” added Dr. Albitar.

For more information about accessing GTC Interpret platform and for more information on Interprestation software suite and how it can benefit your practice, please visit www.genomictestingcooperative.com.

Forward Looking Statements

All the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on the GTC management’s current expectations and includes statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, software, and the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.